Orchestra BioMed Holdings Inc. (OBIO) - Total Liabilities
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has total liabilities worth $61.07 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Orchestra BioMed Holdings Inc. to assess how effectively this company generates cash.
Orchestra BioMed Holdings Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check OBIO financial resilience to evaluate the company's liquid asset resilience ratio.
Orchestra BioMed Holdings Inc. Competitors by Total Liabilities
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
Turkey | TL1.88 Billion |
|
PTC India Financial Services Limited
NSE:PFS
|
India | Rs23.73 Billion |
|
DAEA TI Co. Ltd
KQ:045390
|
Korea | ₩145.62 Billion |
|
UJU Electronics Co. Ltd
KQ:065680
|
Korea | ₩82.83 Billion |
|
Re Max Holding
NYSE:RMAX
|
USA | $617.05 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
USA | $20.91 Million |
|
Creditwest Faktoring AS
IS:CRDFA
|
Turkey | TL1.37 Billion |
|
New Era Energy & Digital, Inc.
NASDAQ:NUAI
|
USA | $10.49 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Orchestra BioMed Holdings Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OBIO market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orchestra BioMed Holdings Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orchestra BioMed Holdings Inc. (2020–2024)
The table below shows the annual total liabilities of Orchestra BioMed Holdings Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $43.22 Million | +59.06% |
| 2023-12-31 | $27.17 Million | -36.87% |
| 2022-12-31 | $43.04 Million | -49.22% |
| 2021-12-31 | $84.76 Million | -2.16% |
| 2020-12-31 | $86.63 Million | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more